Test Bank for Patient Centered Pharmacology by Tindall

Test Bank for Patient Centered Pharmacology by Tindall

Chapter 1. Conscientious and Rational Prescribing in the 21st Century

Multiple Choice

Identify the choice that best completes the statement or answers the question.

____             1. Which statement regarding herbals, vitamins, minerals, and food supplements is true? A. Herbals, vitamins, minerals, and food supplements are not regulated by the U.S. Food, Drug, and Cosmetic Act (FDCA).

B.      Manufacturers must prove the safety of their herbals, vitamins, minerals, and food supplements.

C.      Manufacturers must prove that their herbals, vitamins, minerals, and food supplements are free from adulteration.

D.     Manufacturers must prove the legitimacy of any claims they make about their herbals, vitamins, minerals, and food supplements.

____             2. Which amendment to the FDCA established the two classes of drugs: legend or prescription only and over the counter?

A. Durham-Humphrey Amendment (Prescription Drug Amendment) B. New Drug Application Amendment

C.      Health Education and Welfare Amendment

D.     Kefauer Harris Amendment

____             3. The package insert (PI) attached to a prescription drug contains all of the following information except:

A.     U.S. Food and Drug Administration (FDA)-approved drug information.

B.      Highly detailed adverse effects and dosage information for the prescriber.

C.      Information in layman’s terms for the patient.

D.     Pharmacodynamic and pharmacokinetic drug information.

____             4. Which of the following best defines the term adulteration of drugs? A. Adding contaminants or anything not stated on a drug label

B.      Claiming a drug is a cure for a certain condition, such as cancer

C.      Advertising a drug for a poorly defined condition, such as miasma

D.     Claiming a drug is safe when its safety has not been established in preclinical trials

____             5. The majority of “off-label” or unapproved usages for drugs are prescribed for which patient groups?

A.     Pediatric patients and patients on chemotherapy

B.      Patients with neurologic diseases

C.      Obese patients

D.     Pregnant patients

____        6. The major goals of the Controlled Substances Act (CSA) include all of the following except:

A. Improving the manufacturing, distribution, prescribing, and dispensing of controlled substances by legitimate persons in the health-care sector. B. Providing research into issues of drug addiction and rehabilitation.

C.      Stopping the widespread diversion of controlled substances into illicit or “street” channels.

D.     Establishing laws and criminal sentences for the possession and sale of illicit controlled substances.

____             7. Which statement is true regarding the Drug Enforcement Administration (DEA) categories of scheduled drugs?

A.     Schedule I drugs have a high potential for abuse and no accepted medical use in the United States.

B.      Schedule I drugs have a low potential for abuse and no accepted medical use in the United States.

C.      Schedule II drugs have a low potential for abuse.

D.     Schedule V drugs have a high potential for abuse.

____        8. Which statement regarding extemporaneous compounding is false?

A.     Extemporaneous compounding is the pharmacist’s art of preparing a drug product for a specific patient using a physician’s prescription, a drug formula, or a recipe.

B.      Calculated amounts of ingredients are measured out and made into a uniform mixture.

C.      Extemporaneous compounding is the pharmacist’s art of preparing a drug product for a patient using his own drug formula rather than a physician’s prescription.

D.     Pediatric dosages are commonly compounded when only adult dosages are available.

____        9. Clinical pharmacology is best defined as:

A.     The study of the optimum use of medication in patients.

B.      The study of the human body’s reaction to a drug over a specified time.

C.      The biologic actions of a drug at its site of action.

D.     The study of the effects of genetic variations on pharmacologic processes.